Acrux (ACR)

Shares / Stock Code

ACR

Stock Exchange / Sharemarket

Australian Securities Exchange

Acrux (ACR) is a pooled development fund which invests primarily in pharmaceutical businesses developing new products involving the delivery of pharmaceuticals via the skin. ACR was listed on the Australian Stock Exchange (ASX) on 29 September, 2004. Acrux is engaged in the pharmaceutical research and development industry in the field of dynamic drug delivery, the development and commercialization of healthcare products. Acrux's first product, "EvaMist", has been approved by United States Food and Drug Administration (FDA). Other products by the company in the pipeline include: Testosterone MDTS, Nestorone MDTS and Fentanyl MDTS.

The company owns the proprietary transdermal drug delivery technology which allows certain drugs to be given cleanly, safely and reliably through the skin. Acrux's transdermal drug deliver system is less messy, standarised dosages and continuous blood levels are its benefits of use. The technology is ahead of competitors because of its ability to create an invisible reservoir of active drug just under the surface layer of the skin. This prevents the drug from being inadvertently washed off or transferred to another person through skin contact. The reservoir also ensures gradual seepage into the bloodstream with the desirable effect that constant blood levels can be maintained.

Acrux Company History

Acrux was first formed in 1998 after the development of the transdermal drug technology at Monash University. ACR had raised $26M in three rounds of private funding before public listing and also received $4M of grant funding. These funds were used to build a management team for the company and push seven compounds into the clinical trials phase.

Acrux (ACR) Products and Services

  • Drug Delivery Systems:
    • Research and development in the pharmaceutical industry in the area of menopausal symptoms
    • Hormonal related
    • Contraception
    • Chronic pain
    • Male testosterone deficiency
    • Pet health

Acrux Competitors

  • Alza
  • Noven
  • Biosante

Acrux (ACR) Locations and Subsidiaries

Acrux Limited Headquarters
103-113 Stanley St
West Melbourne VIC 3003
Phone: (03) 8379 0100
Fax: (03) 8379 0101
Email: info@acrux.com.au

Acrux Subsidiaries>

Acrux DDS Pty Ltd
Fempharm Pty Ltd
Acrux Pharma Pty Ltd
Cosmeceutic Solutions Pty Ltd

Other Acrux Details

Acrux Year Established: 1998
ACN: 082 001 152
D-U-N-S: 740002092
ABN: 72082001152

Company Website

Acrux (ACR) Share Price

Submitted by Share Trading on 18 June, 2008 - 18:05

Download our FREE App


Signup for Free
Don't miss out on your free share trading articles.


Free Risk Money Management Calculator for those who sign up!